RE:RE:RE:RE:72% CR at any point in time.I hope they have eliminated the first 12 undertreated patents. But I don't think that alone can account for the 12 evaluable patients at 450 days. In the Nov. 29 MD&A there were 29 evaluable patients at 450 days. If we remove the 12 undertreated and the 3 from phase 1 we would have 14 patients. It has been 5 months since Nov 29 and 5 patients who were evaluated at 360 days should now also have been evaluated at 450 days. That would make 19 patients evaluated at 450 days. There are now only 12.
enriquesuave wrote: wildbird1 wrote: NotinKansas, you start your post exactly the same way that greaterfoolfred does, by saying something that is misleading.
You pretend that the NR patients collect at the bottom. How do you explain patient 22 , this patient is NR from 90 days up to 360 days, and he is not at the bottom of the Swimmer plot.
And there is absolutely no mention anywhere in any Pressrelease that say that the NR patients are send at the bottom of the Swimmer list.
It's obvious from chart and swimmers plot mirrors chart. 52 patients plus 4 non evaluable patients for a total of 56. Includes 12 undetreated at 90 days. Other time points the 12 under treated were removed. Now if in another trial patients were to be given 100 mg of a drug, but 12 patients were wrongly given 15-59 mg ( or 15-59% of intended dose), why in the hell should they be included in final data? Only to be used in safety analysis perhaps? That's what happened with the 12 under treated. It was just a matter of time before removal from data. IMHO